OMA Logo

Welcome to the OMA Blog

The Obesity Medicine Association Blog is the leading industry hub for obesity medicine. Find the latest research, expert insights, and practical tips to tackle the multifaceted disease of obesity. Hear from OMA Outreach Committee members, OMA Board members, and more to gain a deeper understanding of the complex factors influencing obesity and explore innovative approaches to prevention, treatment, and long-term management. Join a community of healthcare professionals, researchers, and individuals passionate about combating obesity.

Obesity Medicine Association logo
02/29/24

March 2024 Member Story

Discover the Spark Behind Mark Schwartz Laying the Foundation Mark Schwartz, MD, FOMA, became interested in obesity medicine after one of his colleagues and mentors introduced him to the Obesity Medicine Association. He realized that obesity medicine was his calling and wanted to dedicate 100% of his practice to treating this chronic disease. In 2016, Mark attended his first Obesity Medicine Association conference in Chicago. By being part of the CME committee, he can give back to the OMA and help ensure that future obesity medicine specialists have access to high-quality educational content. Mark's advice to future obesity medicine specialists is to treat obesity as the root cause of their patients’ chronic medical conditions. While the disease of obesity is complex and may take more time during an encounter, the impacts on your patients’ life and satisfaction of watching their overall health improve are worth the investment.” When Mark is not practicing obesity medicine, he enjoys spending time with his wife and son.

Continue reading
Nutrition low carb diet pediatrics
02/21/24

Pediatric Research Update | Low-Carbohydrate Diets in Children and Adolescents With or at Risk for Diabetes

Each month, the OMA Pediatric Committee reviews a pediatric-focused obesity research update to help keep you up to date about the latest findings. 

Continue reading
Obesity Medicine Association logo
01/30/24

February 2024 Member Highlight

Two specific member benefits stood out for Natalie in her journey with OMA: the Obesity Algorithm ®, with its highly detailed and organized mass of information, was an invaluable resource in guiding Natalie through the complex landscape of obesity treatment. Natalie shared, “Not only are OMA conferences highly education and extremely inspirational, but I also get to meet some amazing influential people in Obesity Medicine.”

Continue reading
Image of a doctor wearing a white coat with a stethoscope around their neck, holding a prescription pad up to the camera with the orange Obesity Medicine Association logo in the bottom right corner
01/26/24

Top Weight Loss Medications

Discover the most effective weight loss medications approved by the FDA. Comprehensive guide on safety, dosage, and efficacy for 2024.

Continue reading
Obesity Medicine Association logo
01/23/24

Pediatric Research Update | Adipokines: Deciphering the cardiovascular signature of adipose tissue.

Each month, the OMA Pediatric Committee reviews a pediatric-focused obesity research update to help keep you up to date about the latest findings. 

Continue reading
Obesity Medicine Association logo
01/20/24

Weight Loss Medication Side Effects: Know Before You Start

Learn about the side effects of weight loss drugs, from digestive issues to long-term impacts. Get the facts before starting your regimen.

Continue reading
two doctors standing next to each other holding clipboards
01/08/24

Leading Obesity Expert Organizations Release Statement to Patients on Compounded GLP-1 Alternatives

Today, there's renewed optimism due to the emergence of GLP1-based drug therapies like Wegovy (semaglutide) and Zepbound (tirzepatide), which demonstrate remarkable effectiveness for weight and health. Unfortunately, many of the available alternatives, like compounded versions of semaglutide and tirzepatide, are not what they are advertised to be. These companies stated that they do not sell the active ingredient to compounding pharmacies, and substances made or distributed by compounding pharmacies or other healthcare practitioners that claim to be semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) have not been reviewed by the FDA for safety, quality, or efficacy. For more information, see the following details: Compounded peptides: An Obesity Medicine Association Position Statement - ScienceDirect | Obesity Medicine Association Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss | FDA Compounding and the FDA: Questions and Answers | FDA Open Letter Regarding the Use of Mounjaro® (tirzepatide) and Zepbound™ (tirzepatide) | Eli Lilly and Company Responsible Use Letter | Novo Nordisk Things You Should Know About Compounded Anti-Obesity (AOM) Medications | Obesity Medicine Association

Continue reading
Obesity Medicine Association logo
01/04/24

January Member Highlight

Chelsea Wiltjer Yost, MD, is a Medical Director & Obesity Medicine Specialist for Emory Bariatric Center and Assistant Professor of General Internal Medicine at Emory University School of Medicine

Continue reading
Obesity Medicine Association logo
12/30/23

Why Obesity is a Disease

In 2013, the AMA declared that obesity is a disease, a controversial claim that has sparked debate. OMA explains why we believe that obesity is a disease.

Continue reading

Showing 10-18 of 183 results

1 2 3 ... 21